Background-In a large population-based study, we aimed to determine whether children born to women with systemic lupus erythematosus (SLE) have an increased risk of congenital heart defects (CHDs) in comparison with children born to women without SLE. Methods and Results-The Offspring of SLE Mothers Registry (OSLER) includes all women who had ≥1 hospitalization for delivery after SLE diagnosis, identified through Quebec's healthcare databases , and a randomly selected control group of women, matched ≥4:1 for age and year of delivery. We identified children born live to SLE mothers and their matched controls, and ascertained CHD based on ≥1 hospitalization or physician visit with relevant diagnostic codes, within the first 12 months of life. We performed multivariable logistic regression analyses, using the generalized estimating equation method, to adjust for relevant covariates. Five hundred nine women with SLE had 719 children, whereas 5824 matched controls had 8493 children. 
S ystemic lupus erythematosus (SLE) predominantly occurs in women of childbearing age, with prevalence estimates of ≈1.5/1000 in females aged 18 to 44 years. 1 This disease can cause considerable morbidity during pregnancy. Pregnant women with SLE and those contemplating pregnancy often ask if their disease will affect their baby. Although several studies have evaluated obstetric outcomes in lupus pregnancy, little is known about the risk of congenital anomalies.
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Congenital heart defects (CHDs) are the most frequent type of birth defects, accounting for approximately one-third of all congenital anomalies 2 ; they are associated with substantial child morbidity. 3 In utero exposures, such as maternal illnesses and medications, are thought to play an important role in the yet to be fully elucidated etiology of CHD. 4 In particular, a recent study suggests a 3-fold increased risk of CHD in children born to mothers with various systemic connective tissue disorders, including SLE. 5 However, the investigators did not specifically assess the SLE effect estimate for the risk of CHD and did not control for medication exposures. Certain drugs used to treat SLE manifestations, such as methotrexate and mycophenolate mofetil, are known teratogens, and affected women might be inadvertently exposed to these agents during pregnancy, potentially increasing the risk of CHD. 6 Only very few uncontrolled observational studies have assessed CHD in offspring of mothers with SLE. Notably, in a study of fetal echocardiography in a small number of SLE pregnancies, 7 7.5% of fetuses had a CHD, which is >5-fold what is usually observed among live births from the general population (0.6%-1.3%), although that is clearly not an equivalent comparison group. 8 Investigators have also observed CHD in 16% to 42% of children with congenital heart block born to mothers with anti-Ro/SSA antibodies, after excluding cases with CHD 150 Circulation January 13, 2015
that could have caused congenital heart block. [9] [10] [11] [12] [13] Although the prevalence of CHD was lower in children born to mothers with anti-Ro/SSA antibodies who did not develop congenital heart block (2.8%), the frequency was still substantially higher than in the general population. 9 In such studies, the most frequently observed CHDs were atrial septal defects (ASDs), ventricular septal defects (VSDs), and valve anomalies. [9] [10] [11] [12] [13] Given the paucity of existing literature, we aimed, in a large population-based study, to determine whether children born to women with SLE have an increased risk of CHD in comparison with children born to women without SLE. In addition, we aimed to determine if the offspring of SLE mothers have an increased risk of particular CHD subtypes, including ASD, VSD, and valve anomalies, in comparison with the offspring born to unaffected mothers.
Methods

Study Design and Subjects
The Offspring of SLE Mothers Registry (OSLER) is a population-based cohort of 719 children born to mothers with SLE, matched to 8493 control children. To create this large cohort, we identified all women with SLE who had ≥1 hospitalization for a delivery resulting in a stillbirth or live birth, between January 1989 and December 2009, using data from the Quebec Maintenance et Exploitation des Données pour l'Étude de la Clientèle Hospitalière (MED-ECHO) hospitalization and Régie de l'Assurance Maladie du Québec (RAMQ) physician billing databases.
MED-ECHO is the administrative database collecting information on all hospitalizations in Quebec since 1987 and provides, for each hospitalization, a primary discharge diagnosis and ≤15 nonprimary diagnoses, captured as International Classification of Diseases, Ninth Revision (ICD-9) codes, and since 2006, International Classification of Diseases, Tenth Revision (ICD-10) codes. The RAMQ billing database records 1 physician-assigned diagnosis, based on ICD-9 codes, for each physician encounter.
Exposure of Interest
Women were identified as SLE cases, based on a validated definition, 14 with the use of ICD-9 code 710.0 or ICD-10 code M32, if they had any of the following: (1) ≥1 hospitalization with a diagnosis of SLE, either primary or nonprimary, before the delivery; (2) a diagnosis of SLE, either primary or nonprimary, recorded at the time of their hospitalization for delivery; or (3) ≥2 physician visits with a diagnosis of SLE, occurring 2 months to 2 years apart, before the delivery. From these databases, a general population control group was composed of women individually matched ≥4:1 for age and year of delivery, who did not have a diagnosis of SLE before or at the time of delivery.
Mother-child linkage was done by using the encrypted mother's number, which is present in every child's file in the RAMQ and MED-ECHO databases, and where it remains through childhood, leading to very few linkage failures (<2%). Those children born live were the basis of the OSLER cohort for outcome ascertainment, one being the exposed group consisting of children born to women with SLE, and the other being the control group consisting of children born to women without SLE. Stillbirths were not included because a substantial proportion of stillbirths in Quebec result from pregnancy termination, for which no information for our outcome of interest is recorded either for SLE mothers or for controls (see online-only Data Supplement).
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Outcome Assessment
The cohort of children described above was linked to the MED-ECHO and RAMQ databases to determine hospitalizations and all diagnoses occurring throughout the study interval of these offspring. This study interval spanned from birth to the first of the following: end of eligibility for RAMQ coverage (ie, migration from Quebec), event of interest (eg, CHD), age 1, death, or end of study (ie, December 31, 2009).
Our ascertainment of CHD in live-born babies was based on the presence, at birth or within the first 12 months of life, of ≥1 ICD-9 codes 745, 746, and 7471 to 7474 and ICD-10 codes Q20 to Q26, using the methodology developed by the European Surveillance of Congenital Anomalies network. 16 The use of ICD-9 and ICD-10 codes for identification of CHD has been previously validated in Quebec's administrative databases. 17 We further excluded subjects with ICD-9 and ICD-10 codes referring to congenital heart block and patent ductus arteriosus as the only CHD. However, subjects with a diagnosis of congenital heart block and patent ductus arteriosus and any other CHD were included as cases. ASD, VSD, and valve anomalies were defined based on ≥1 relevant diagnostic code (see online-only Data Supplement). We included records of CHD diagnosed within the first 12 months of life to capture events with delayed detection or registration.
Assessing Relevant Covariates
For all mothers in our study, we reviewed the MED-ECHO and RAMQ data to identify specific preexisting and current comorbidities (ie, hypertension, pregestational diabetes mellitus, asthma) recorded in the 2 years before the time of delivery, and obstetric complications, as well, such as gestational diabetes mellitus, at the time of the hospitalization for delivery. The diagnosis of specific comorbidities listed above was based on ICD-9 and ICD-10 codes indicating ≥1 hospitalization or ≥2 physician visits, at least 8 weeks apart, for the diagnosis of interest, as per previously validated methodology. 18, 19 Available through the Institut de la Statistique du Québec were data on the demographics of the parents at the time of delivery, including maternal education, and maternal and paternal birthplace, maternal language, and language spoken at home, as well, which were used to establish the race/ethnicity of the offspring (see online-only Data Supplement). These demographic data were used in our analyses as covariates.
Comprehensive and valid data on drug exposures are available from the RAMQ prescription (RAMQ-Rx) database, but only for beneficiaries of the public drug plan. 20 The RAMQ-Rx plan covers recipients of social assistance and workers and their families who do not have access to private drug insurance. In our cohort, 22% of exposed children and 21% of controls were born to a mother with RAMQ-Rx plan coverage throughout pregnancy.
In this subgroup, we obtained all information on the prescription of certain types of medications, including corticosteroids, antimalarials, immunosuppressives, antidepressants, and anticonvulsants. It is noteworthy that there is no information recorded on intravenous cyclophosphamide exposure in the RAMQ-Rx database, because this medication is administered in hospital. We used gestational age recorded at birth to calculate back to the estimated start of the gestational period, then determined whether a medication exposure of interest ever occurred during pregnancy based on ≥1 prescription filled at any time during gestation.
Statistical Analysis
We calculated the prevalence and computed the odds ratios (ORs) for all types and specific subtypes of CHD in the group of children born to mothers with SLE versus the control group, performing both univariable and multivariable regression analyses estimated with generalized estimating equations. 21 Missing data on education and race/ ethnicity covariates, occurring in <6% of subjects, were handled by using multiple imputation (see online-only Data Supplement).
In these analyses, we matched SLE exposed and unexposed children for maternal age group and calendar year of delivery, but we also further adjusted for maternal age and calendar year to control for potential confounding by these variables (see online-only Data Supplement). In addition, we adjusted for relevant demographic factors and maternal comorbidities, including the following: sex of child, birth order, maternal education, race/ethnicity, pregestational and gestational diabetes mellitus, maternal hypertension, and asthma. In the subsample with RAMQ-Rx plan coverage, we also adjusted for in utero maternal medication exposures, including corticosteroids (ie, oral or intravenous corticosteroids), antimalarials (ie, hydroxychloroquine or chloroquine), immunosuppressives (ie, azathioprine, mycophenolate mofetil, mycophenolate sodium, and methotrexate), and any types of antidepressants. Of note, we excluded exposure to by guest on April 15, 2017 http://circ.ahajournals.org/ Downloaded from anticonvulsants from the subsample multivariable model because no CHD case was recorded for this covariate.
Moreover, we performed a sensitivity analysis to account for the possibility of detection bias. Indeed, the offspring of SLE mothers are more likely to undergo fetal echocardiography as part of routine screening to detect congenital heart block in those exposed in utero to maternal anti-SSA/Ro and anti-SSB/La antibodies, which are present in up to 40% of women with SLE. 22 Hence, CHD might be more easily detected in children born to women with SLE than in controls, leading to an overestimation of the association. Thus, to account for this possibility, we reran the analysis excluding children who had ≥1 fetal echocardiography.
In addition, to investigate the clinical impact of a potentially increased risk of CHD in SLE offspring versus controls, we further assessed the risk of CHD repair procedures (see online-only Data Supplement), adjusting for the potential confounders mentioned above, with the exception of medication, owing to the small number of procedure events in the subsample with public drug coverage.
The study was approved by the Commission d'Accès à l'Information du Québec and the McGill University Research Ethics Board. Informed consent is not required for administrative database research in Quebec. The first author takes full responsibility for the accuracy and completeness of the data.
Results
Five hundred nine women with SLE had 719 children, whereas 5824 matched controls had 8493 children. Mean maternal age in the overall sample of mothers and mean SLE disease duration were, respectively, 30.3 (standard deviation[ SD], 5.0) and 3.7 (SD, 4.0) years (Table 1 ). Mothers with SLE had similar demographic characteristics in comparison with control mothers, with the exception of race/ethnicity because they were less likely to be white (as expected, because black and Asian race/ethnicity may predispose to SLE). 1 In addition, mothers with SLE had more comorbidities and experienced substantially more obstetric complications, such as preterm births and preeclampsia/eclampsia, in comparison with control mothers. In utero drug exposures were more frequent in SLE offspring than in controls, with exposures to corticosteroids and antimalarials being the most common drugs prescribed during SLE pregnancies. Among the 11 children with in utero immunosuppressive exposures, all were exposed to azathioprine, with 7/11 having ≥3 records of the drug dispensed, and 1 child was additionally exposed to mycophenolate mofetil, albeit with only 1 record of the drug dispensed early in gestation.
In comparison with controls, children born to women with SLE experienced more CHD (5.1% [95% confidence interval (CI), 3.7-7.1] versus 1.9% [95% CI, 1.6-2.2], difference 3.2% [95% CI, 1.9-5.2]), including more ASD, VSD, and valve anomalies ( Table 2 ). In offspring with maternal drug coverage throughout pregnancy (n=1925), we observed 5 cases of CHD (4 born to SLE mothers and 1 to a control mother) among the 46 children exposed to corticosteroids, and 1 case of CHD in the 11 children exposed to immunosuppressives, all born to SLE mothers.
In multivariable analyses including all children (n=9212), children born to women with SLE had a substantially increased risk of CHD (OR, 2.62; 95% CI, 1.77-3.88) in comparison with controls (Table 3) . Specifically, offspring of SLE mothers had substantially increased odds of ASD (OR, 3.32; 95% CI, 1.97-5.77), VSD (OR, 2.50; 95% CI, 1.31-4.75), and valve anomalies (OR, 2.95; 95% CI, 1.23-7.07) in comparison with controls. Other predictors of CHD included pregestational diabetes mellitus and asthma (Table 3) .
There was an imbalance between the 2 groups in terms of fetal echocardiography, with 16.3% of SLE offspring having ≥1 fetal echocardiography in comparison with 2.5% of control children. When accounting for the possibility of detection bias by excluding children with ≥1 fetal echocardiography (n=331) from the multivariable analyses, adjusted effect estimates were similar to the primary multivariable analysis results for CHD and all subtypes of CHD (Table 4) . †Denominator used for proportion is number of children born to control mothers with public drug coverage during pregnancy. January 13, 2015
In the subsample analysis controlling for maternal medications (Table 5) , although the effect estimates for the association of ASD (OR, 2.05; 95% CI, 0.66-6.37) with maternal SLE remained similar to the primary multivariable analysis result, the 95% CI was wide and included the null value owing to reduced sample size (155 SLE offspring and 1770 controls). In addition, after adjusting for maternal medication exposures, results were inconclusive for the risk of CHD and specifically VSD in SLE offspring in comparison with controls. However, we observed an effect of corticosteroid exposure on the likelihood of CHD (OR, 5.65; 95% CI, 1.65-19.34), after adjusting for both pregestational and gestational diabetes mellitus. Of note, we could not perform a multivariable analysis adjusting for medication exposure for the outcome of valve anomaly, because no case was observed in SLE offspring in the subsample with provincial drug coverage.
Among children with CHD, those born to SLE mothers had more CHD repair procedures than controls (10.5% [95% CI, 2.9-24.8] versus 3.7% [95% CI, 1.4-7.9]; Table 6 ). In addition, in comparison with controls, offspring of SLE mothers had a substantially increased likelihood of having a repair procedure for any type of CHD (OR, 5.82; 95% CI, 1.77-19.09), and specifically having a cardiac septal defect repair procedure (OR, 4.95; 95% CI, 1.22-20.07), after adjusting for relevant covariates.
Discussion
In comparison with children from the general population, children born to women with SLE have an increased risk of CHD, including a specifically increased risk of ASD, VSD, and valve anomalies. In addition, offspring of SLE mothers have substantially increased odds of CHD repair procedures in comparison with children from the general population. The effect of SLE on all types of CHD does not seem to be explained by detection bias and might be independent of medication exposures. Because of the limited power afforded by the sample of subjects who had provincial drug coverage, the findings of analyses limited to this subgroup are inconclusive, although they still point to an increased risk of CHD, regardless of medication exposure.
We found an association between in utero exposure to corticosteroids and CHD, although the CI was wide. Several studies have investigated the potential association between in utero corticosteroid exposure and congenital anomalies, but despite a potential and still controversial increased likelihood of oral cleft defects, no excess risk has been seen for other types of congenital anomalies, in particular, cardiac. 23 The effect of corticosteroid exposure on CHD observed in our study might be explained in part by confounding by disease severity. Indeed, if SLE itself has a causal effect on CHD (eg, mediated through inflammation and autoantibodies), and women with more severe SLE are more likely to have active disease during pregnancy and require corticosteroids for disease control, then confounding by disease severity is likely to have occurred and account for some of the apparent effect of corticosteroid exposure.
We observed that pregestational diabetes mellitus was a potentially important predictor of CHD and all subtypes investigated. It is well recognized that, in the conception period and the first trimester of pregnancy, maternal hyperglycemia can cause diabetic embryopathy resulting in major congenital anomalies. 24 The most frequent type of major congenital anomalies seen in women with pregestational and gestational diabetes mellitus is CHD. 24 Previous studies have shown that the likelihood of CHD was highest in women with pregestational diabetes mellitus in comparison with those with gestational diabetes mellitus (respectively, 3-fold and 1.5-fold increased risk relative to healthy women). 25, 26 We observed similar effect estimates, suggesting that our findings are consistent with published literature on diabetic embryopathy.
The strength of our study resides in the use of Quebec's administrative databases, which collect information on all deliveries performed in the province, allowing us to create OSLER, the largest cohort of children born to mothers with SLE ever assembled. In addition, Quebec's administrative databases are a valid data source for the conduct of observational studies, with previous work from our group showing that our SLE case definition has a very high specificity (0.99).
14 Of note, 16% of SLE children were exposed in utero to antimalarial drugs, which are used to prevent SLE flare. This is comparable to exposure in SLE pregnancies observed over a similar time period and from a wellestablished tertiary care lupus cohort, where 22% were exposed to antimalarials beyond the first trimester. 27 Furthermore, a recent study assessed the validity of pregnancy-related variables recorded in the RAMQ, MED-ECHO, and ISQ databases, such as gestational age and live births, and showed very high sensitivity (0.97-0.99) and specificity (0.92-0.98) for all the variables examined, concluding that these administrative databases are a valid data source for pregnancy-related variables. 28 We used a widely accepted definition of CHD based on ICD-9 and ICD-10 diagnostic codes established by the European Surveillance of Congenital Anomalies network. 16 In addition, a recent study assessed the validity of ICD-9 and ICD-10 diagnostic codes for major congenital anomalies, including CHD, recorded in Quebec's administrative databases. 17 Those investigators used Values are presented as n (%). ASD indicates atrial septal defect; CHD, congenital heart defect; SLE, systemic lupus erythematosus; and VSD, ventricular septal defect.
*Isolated is defined as a specific subtype of CHD occurring without any other subtype of CHD.
†Among cases with other CHDs, but without ASD, VSD, and valve anomalies, the most frequent diagnosis in SLE offspring cases was pulmonary artery anomaly (2/4), whereas, in control cases, it was CHD not otherwise specified (12/34).
by guest on April 15, 2017 http://circ.ahajournals.org/ Downloaded from medical chart as the gold standard and evaluated the performance of relevant diagnostic codes recorded during the first year of life in children born to asthmatic women in comparison with children born to nonasthmatic women. Results were similar between both groups; in particular, both the positive predictive value of CHD and the negative predictive value for any type of congenital anomalies were high (both >94%). 17 Because asthma is one of the most frequent chronic diseases encountered during pregnancy, with potential for disease exacerbation, similar to SLE in pregnancy, it is of interest to note that there was no differential ascertainment of congenital anomalies in offspring of affected women in comparison with controls. We would hope, although we cannot be sure, that there would similarly be no differential ascertainment of congenital anomalies in the offspring of women affected by SLE in comparison with controls.
Still, we accounted for the possibility of detection bias owing to the more frequent use of fetal echocardiography in SLE pregnancies, which is a considerable strength of our study. After ASD indicates atrial septal defect; CHD, congenital heart defect; CI, confidence interval; OR, odds ratio; SLE, systemic lupus erythematosus; and VSD, ventricular septal defects. excluding children who had ≥1 fetal echocardiography, the effect estimates for all types and subtypes of CHD were similar in comparison with the overall analysis results. However, this sensitivity analysis did not account for subtle forms of detection bias that might have occurred after delivery. Indeed, mothers with SLE might be more concerned that their child develops a health problem than control mothers, and they might seek medical attention for their offspring more frequently. If this were the case, it would increase the number of CHD cases diagnosed in children born to SLE mothers, particularly minor and asymptomatic cases. To strengthen our case, we found a substantially increased risk of CHD repair procedures in offspring of SLE mothers in comparison with controls, which does not suggest that detection bias occurring after the pregnancy solely explained the observed association between CHD and maternal SLE.
Our study has some potential limitations. As mentioned previously, the subsample analysis accounting for relevant medication exposures did not allow us to precisely estimate the association between maternal SLE and CHD in offspring because of the limited power given by the reduced sample of subjects with provincial drug coverage. Regardless, this is the largest study to date assessing the risk of CHD in SLE offspring.
Another potential limitation is that medication exposures were defined based on filled prescriptions, which might not have reflected actual intake. However, it is likely that most women who filled a prescription for a specific medication took at least 1 dose, because, within the RAMQ prescription plan, beneficiaries need to cover part of their medication cost. 29 In addition, in all observational studies, unmeasured or poorly measured confounding represents a major concern. We have considered this and used well-defined proxies for certain variables (eg, socioeconomic status, race/ethnicity). Still, administrative databases do not contain information on, for example, smoking, obesity, or alcohol use, which have all been associated with an increased risk of having a child with CHD in exposed pregnant women. However, previous data from Quebec suggest that smoking practices, obesity prevalence, and alcohol use in SLE patients are comparable to the general population. 30 Therefore, the lack of information on these variables is unlikely to have introduced substantial bias.
Other limitations include our inability to adjust for folic acid and multivitamin exposures during pregnancy, because these supplements are frequently obtained without a prescription (ie, over the counter), and thus not captured in a large proportion of women covered by the RAMQ-Rx plan. Moreover, stillbirths were not included a priori in our analyses because a significant proportion of stillbirths in Quebec result from pregnancy ASD indicates atrial septal defect; CHD, congenital heart defect; CI, confidence interval; OR, odds ratio; SLE, systemic lupus erythematosus; and VSD, ventricular septal defect. termination, for which no information on the outcome of interest is recorded. 15 Still, in our cohort, we observed few stillbirths resulting from pregnancy termination, and the effect estimate for CHD did not change when stillbirths were included in the overall analysis (see online-only Data Supplement).
Furthermore, Quebec's administrative databases do not record serological data on any individual. This would have been of interest particularly in women with SLE to determine if specific types of maternal autoantibodies, such as anti-Ro/SSA and antiphospholipid antibodies, predict CHD in children born to women with SLE. Still, establishing an association between in utero SLE exposure and CHD shed new light on the potential role of maternal autoantibodies and cytokines in CHD pathogenesis.
Indeed, maternal SLE-related mechanisms that could be implicated in the physiopathology of CHD in offspring include autoantibody-mediated damage and cytokine imbalance. Transplacental transfer of maternal IgG antibodies begins in the second trimester, reaching circulating levels in the newborn that exceed maternal levels, owing to active transport across the placenta. 31 Anti-SSA/Ro and anti-SSB/La antibodies, found in ≈40% of women with SLE, cross the placenta and are associated with the development of neonatal lupus, with congenital heart block being the most characteristic cardiac manifestation. Investigators have demonstrated that maternal anti-SSA/ Ro and anti-SSB/La antibodies bind apoptotic fetal cardiocytes, resulting in the release of proinflammatory and profibrosing cytokines, and ultimately scarring. 32 This process likely extends beyond the conduction tissue, involving the myocardium, endocardium, and valves. In a recent retrospective analysis of autopsies from 18 cardiac neonatal lupus cases, cardiac histological damage outside the conduction system was frequently observed. 12 In particular, 1 autopsy showed a lymphohistiocytic infiltrate with inflammatory giant cells in the ventricular septum, whereas another displayed foci of microscopic calcification in the atrial septum. Moreover, 40% (6/15) of deaths attributable to congenital heart block had pathology findings such as fibrosis and calcification of the valves and valve apparatus, including the tricuspid, mitral, aortic, and pulmonary valves. 12 Cardiac septation occurs early in embryogenesis and is complete by 6 weeks of gestation. 33 Because transplacental passage of maternal autoantibodies only occurs as early as the 20th week of gestation, it is unlikely that maternal autoantibodies directly interfere with cardiac septation. However, muscular VSDs, which account for ≈75% of all VSDs, are thought to arise from foci of cellular death that occur during active cardiac remodeling, within an already formed ventricular septum. 34 In addition, maternal autoantibodies might prevent closure of cardiac septal defects that might have closed otherwise, possibly explaining the excess risk of cardiac septal defects in offspring of SLE mothers in comparison with controls.
Antiphospholipid antibodies (aPLs) are another type of autoantibodies commonly found in women with SLE, which also cross the placenta. In a recent study of children born to women with antiphospholipid syndrome, 40% of neonates had positive aPL in cord blood. 35 aPLs are strongly associated with valvular disease (eg, valvular nodules, regurgitation, and verrucous endocarditis) in aPL-positive adult patients with and without SLE. 36 Valvular deposits of aPLs in affected adult subjects are thought to play an important pathogenic role in valvular disease. 36 Although previous studies have reported perinatal thrombotic events occurring in children born to aPLpositive mothers, there are currently no data on the prevalence of congenital valve anomalies or other types of CHDs in these children. 37 Because aPLs are involved in valvular damage in seropositive adult subjects and cross the placenta, it could be hypothesized that they may play a role in valve anomalies in exposed fetuses.
Cytokines, such as transforming growth factor beta (TGF-β), play an important role in cardiac embryogenesis. In particular, adequate endocardial cushion formation, which is a critical step in cardiac septation, requires expression of TGF-β. 38 The importance of both maternal and fetal TGF-β in cardiac embryogenesis has been well illustrated in animal models. 38 Notably, TGF-β-1-null mice, born to TGF-β-1-null mothers, demonstrate severe CHD, whereas TGF-β-1-null mice born to wildtype mothers (ie, with normal expression of TGF-β-1) do not. Because transplacental transfer of circulating TGF-β can occur from mother to fetus, investigators hypothesized that maternal TGF-β-1 might rescue any potential heart defects in the null offspring. 38 Interestingly, in SLE patients, serum levels of TGF-β-1 are substantially lower than in controls, with levels inversely correlating with disease activity. 39 Thus, maternal TGF-β rescue of fetuses with defective TGF-β levels might not occur in women with SLE, potentially accounting for the increased risk of CHD.
In conclusion, children born to women with SLE have an increased risk of CHD, including a specifically increased risk of ASD, VSD, and valve anomalies, in comparison with children from the general population. In addition, offspring of SLE mothers have substantially increased odds of CHD repair procedures in comparison with children from the general population. Our findings prompt further research to elucidate the potential role of disease-related factors, such as in utero drug exposures, maternal autoantibodies and cytokines, which might explain the increased likelihood of CHD in children born to mothers with SLE. 
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Supplemental Methods
For this study, we worked in collaboration with the "Régie de l'Assurance Maladie du Québec (RAMQ)" which manages both the MED-ECHO and physician billing databases. The RAMQ employs skilled data analysts, who extracted the data, according to our pre-specified requirements, to create the exact dataset needed for our study. Only information judged useful for the conduct of the study was transmitted to the research team, as data managed by the RAMQ is highly restricted by the "Commission d'accès à l'information du Québec". Therefore, we only had access to the cohort once it was created. We verified that the cohort conformed to our selection criteria (i.e.
appropriate SLE case definition, matching with controls, etc). However, we do not have information on women who were not included in our study and could not produce a flow diagram illustrating the subject selection from the source population.
Stillbirths were not included in our analyses because a significant proportion of stillbirths in Quebec result from pregnancy termination, for which no information on the outcome of interest is recorded. In Quebec, information on stillbirths are recorded based on the following definition: death prior to the complete expulsion or extraction from its mother of a product of conception weighing 500 or more grams, regardless of the gestational age. Since pregnancy terminations are performed up to 24 weeks of gestation in Quebec, some fetal deaths are labeled as stillbirths even if they result from a pregnancy termination.
In a matched cohort study, ignoring the matching variables can leave bias if there are additional confounders, even when controlling for these additional confounders.
Therefore, control for the matching variables is needed when dealing with matched cohort data, although a matched analysis per se is not required. [1] Models estimated with generalized estimating equations account for the correlation in outcomes of children born to the same mother (i.e. the probability of a congenital anomaly is higher when a sibling has been affected), with each mother serving as the clustering unit. [2] Multiple imputation was performed assuming an arbitrary missing pattern, using a multivariable normal approach via the Markov chain Monte Carlo method, and included the same covariates as the primary multivariable model. Multivariable analysis results
were very similar using either the dataset with missing data or the imputed dataset.
We compared means between SLE offspring and control children with a t-test and proportions with a chi-square test, unless cells were too sparse, in which case we used a two-sided Fisher's exact test.
Results
There were 10 stillbirths among 729 SLE births (1.4%, 95% CI 0.7, 2.6) and 49 stillbirths among 8542 control births (0.6%, 95% CI 0.4, 0.8). For all stillbirths, cause of death was identified in the mandatory stillbirth report form. In the SLE group, one stillbirth was due to pregnancy termination, while no stillbirth was attributed to CHD. In the control group, two stillbirths were due to pregnancy terminations, while one stillbirth was attributed to CHD. The effect estimate for CHD did not change when we included stillbirths in the overall analysis (OR 2.80, 95% CI 1.94, 4.04). 
